FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate CancerJaleh Fallah, Paul G. Kluetz, Sundeep Agrawal et al.|Clinical Cancer Research|2022Cited by 236
FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing ChemotherapyDaniel L. Suzman, Julia A. Beaver, Sundeep Agrawal et al.|The Oncologist|2018Cited by 200
A U.S. Food and Drug Administration–pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell CarcinomaDaniel Lee, Laleh Amiri‐Kordestani, Haley Gittleman et al.|European Urology|2023Cited by 19
Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trialsJaleh Fallah, Harpreet Singh, Lijun Zhang et al.|The Lancet Oncology|2021Cited by 15
Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney CancerSundeep Agrawal, Andrea B. Apolo, Naomi B. Haas et al.|JAMA Oncology|2019Cited by 13